<DOC>
	<DOCNO>NCT01895127</DOCNO>
	<brief_summary>This open-label analysis compare eculizumab versus Plasmapheresis ( PP ) Immunoglobulin ( IVIg ) treatment AMR renal transplant recipient . All patient evaluate time AMR diagnosis 12 month .</brief_summary>
	<brief_title>Efficacy Safety Eculizumab Treatment Antibody-mediated Rejection Following Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Adult renal transplant recipient , men woman 18 75 year age . 2 . Any patient acute graft dysfunction ( elevation creatinine post transplant nadir ) AND , two three , follow 3 . Presence circulate anti HLA antibody ( DSA ) . 4 . Histological finding compatible Banff Class II III AMR transplant biopsy . 5 . Peritubular capillary c4d positivity transplant biopsy . 1 . Patients receive eculizumab prior enrol study . 2 . Patients ongoing nonacute antibody mediate rejection . 3 . Patients predominantly chronic antibody mediate rejection interstitial fibrosis/tubular atrophy . 4 . History severe cardiac disease ( e.g. , New York Heart Association [ NYHA ] Functional Class III IV , myocardial infarction ≤ 6 month randomization , ventricular tachyarrhythmias require ongoing treatment , unstable angina significant cardiovascular disease ) 5 . Prior splenectomy 6 . Has know bleed disorder 7 . Has active bacterial infection clinically significant opinion Investigator contraindication transplantation 8 . Has participate investigational drug study expose investigational drug device within 30 day screen 9 . Has receive rituximab ( Rituxan® ) ≤ 3 month prior screen 10 . Has receive bortezomib ( Velcade® ) ≤ 3 month prior screen 11 . Has receive alemtuzumab ( Campath® ) ≤ 6 month prior screen 12 . Need concurrent treatment anti thymocyte globulin ( Thymoglobulin® ) 13 . Hypersensitivity murine proteins one product excipients 14 . History illicit drug use alcohol abuse within previous year 15 . Unresolved meningococcal disease 16 . Pregnancy lactation 17 . Current cancer history cancer within 5 year prior screen exception patient successfully treat nonmetastatic basal squamous cell carcinoma skin ; carcinoma situ cervix ; breast carcinoma situ 18 . Any medical condition , opinion Investigator , might interfere patient 's participation study , pose added risk patient , confound assessment patient Active infection Hepatitis B ( HBV ) , Hepatitis C ( HCV ) human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Kidney Transplant</keyword>
	<keyword>Renal Transplant</keyword>
	<keyword>Rejection</keyword>
	<keyword>Antibody mediate</keyword>
	<keyword>Humoral</keyword>
	<keyword>Eculizumab</keyword>
</DOC>